Therapie mit Inhibitoren des epidermalen Wachstumsfaktorrezeptors

摘要: Recently, inhibitors of the epidermal growth factor receptor (EGFR), such as erlotinib, gefitinib, cetuximab or panitumumab, have been successfully established in therapy a variety solid tumors. Cutaneous adverse effects are most frequent side-effects these so-called targeted cancer drugs and occur 45-100% patients. In addition to characteristic papulo-pustular rash, include painful paronychia, xerosis cutis, pruritus, alopecia alterations hair structure. These often stigmatizing represent serious threat patients' quality life compliance may lead dose-reduction even cessation antineoplastic therapy. Considering steadily growing numbers patients who receive EGFR-targeting therapy, medicament-associated cutaneous becoming increasingly more important routine clinical practice dermatologists oncologists.